<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-06YCY3OT</identifier><date>2022</date><creator>Hanžel, Jurij</creator><relation>documents/doc/0/URN_NBN_SI_doc-06YCY3OT_001.pdf</relation><relation>documents/doc/0/URN_NBN_SI_doc-06YCY3OT_001.txt</relation><relation>https://repozitorij.uni-lj.si/IzpisGradiva.php?id=135932</relation><format format_type="type">doktorska dela</format><format format_type="extent">V, 89 str., 31 cm</format><identifier identifier_type="COBISSID">140565251</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-06YCY3OT</identifier><language>eng</language><publisher publisher_location="Ljubljana">J. Hanžel</publisher><source>visokošolska dela</source><rights>InC</rights><subject language_type_id="slv">biološka zdravila</subject><subject language_type_id="slv">Crohnova bolezen</subject><subject language_type_id="slv">doktorske disertacije</subject><subject language_type_id="slv">izid zdravljenja</subject><subject language_type_id="slv">kronična vnetna črevesna bolezen</subject><subject language_type_id="slv">ustekinumab</subject><subject language_type_id="slv">vedolizumab</subject><title>doctoral thesis</title><title>doktorska disertacija</title><title>Povezava serumskih koncentracij vedolizumaba in ustekinumaba z izidi zdravljenja pri kronični vnetni črevesni bolezni</title><title>The relationship of serum concentrations of vedolizumab and ustekinumab with treatment outcomes in inflammatory bowel disease</title></Record>